Early development evaluation of AZD2738, a substrate for the NK receptors

References

• Pennefather JN, Lecci A, Candenas ML, Patak E, Pinto FM, Maggi CA. (2004). Tachykinins and tachykinin receptors: a growing family. Life Sci, 74:1445–1463.
   PubMed Web of Science ®Google Scholar
• Quartara L, Altamura M. (2006). Tachykinin receptors antagonists: from research to clinic. Curr Drug Targets, 7:975–992.
   PubMed Web of Science ®Google Scholar
• Holzer P, Holzer-Petsche U. (2001). Tachykinin receptors in the gut: physiological and pathological implications. Curr Opin Pharmacol, 1:583–590.
   PubMedGoogle Scholar
• Naline E, Devillier P, Drapeau G, Toty L, Bakdach H, Regoli D et al. (1989). Characterization of neurokinin effects and receptor selectivity in human isolated bronchi. Am Rev Respir Dis, 140:679–686.
   PubMed Web of Science ®Google Scholar
• Tsuchida K, Shigemoto R, Yokota Y, Nakanishi S. (1990). Tissue distribution and quantitation of the mRNAs for three rat tachykinin receptors. Eur J Biochem, 193:751–757.
   PubMedGoogle Scholar
• Pennefather JN, Zeng XP, Gould D, Hall S, Burcher E. (1993). Mammalian tachykinins stimulate rat uterus by activating NK-2 receptors. Peptides, 14:169–174.
   PubMed Web of Science ®Google Scholar
• Croci T, Aureggi G, Manara L, Emonds-Alt X, Le Fur G, Maffrand JP et al. (1998). In vitro characterization of tachykinin NK2-receptors modulating motor responses of human colonic muscle strips. Br J Pharmacol, 124:1321–1327.
   PubMed Web of Science ®Google Scholar
• Saffroy M, Torrens Y, Glowinski J, Beaujouan JC. (2001). Presence of NK2 binding sites in the rat brain. J Neurochem, 79:985–996.
   PubMed Web of Science ®Google Scholar
• Saffroy M, Torrens Y, Glowinski J, Beaujouan JC. (2003). Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: comparison with NK1 and NK3 binding sites. Neuroscience, 116:761–773.
   PubMed Web of Science ®Google Scholar
• Massi M, Panocka I, de Caro G. (2000). The psychopharmacology of tachykinin NK-3 receptors in laboratory animals. Peptides, 21:1597–1609.
   PubMed Web of Science ®Google Scholar
• Page NM, Bell NJ. (2002). The human tachykinin NK1 (short form) and tachykinin NK4 receptor: a reappraisal. Eur J Pharmacol, 437:27–30.
   PubMed Web of Science ®Google Scholar
• Patak E, Candenas ML, Pennefather JN, Ziccone S, Lilley A, Martín JD et al. (2003). Tachykinins and tachykinin receptors in human uterus. Br J Pharmacol, 139:523–532.
   PubMed Web of Science ®Google Scholar
• Fioramonti J, Gaultier E, Toulouse M, Sanger GJ, Bueno L. (2003). Intestinal anti-nociceptive behaviour of NK3 receptor antagonism in conscious rats: evidence to support a peripheral mechanism of action. Neurogastroenterol Motil, 15:363–369.
   PubMed Web of Science ®Google Scholar
• Lecci A, Maggi CA. (2003). Peripheral tachykinin receptors as potential therapeutic targets in visceral diseases. Expert Opin Ther Targets, 7:343–362.
   PubMed Web of Science ®Google Scholar
• Jankovic B, Mentus S. (2010). Thermal stability and nonisothermal kinetics of Folnak degradation process. Drug Dev Ind Pharm, 36:980–992.
   PubMed Web of Science ®Google Scholar
• Haleblian J, McCrone W. (1969). Pharmaceutical applications of polymorphism. J Pharm Sci, 58:911–929.
   PubMed Web of Science ®Google Scholar
• Threlfall TL. (1995). Analysis of organic polymorphs. A review. Analyst, 120:2435–2460.
   Web of Science ®Google Scholar
• Grant DJW, Higuchi T. (1990). Solubility behavior of organic compounds. New York: Wiley, 600.
   Google Scholar
• Grant DJW, Brittain HG. (1995). Solubility of pharmaceutical solids. In: Brittain HG, ed. Physical characterization of pharmaceutical solids. New York: Marcel Dekker, 321–386.
   Google Scholar
• Brittain HG, Grant DJW. (1999). Effects o f polymorphism and solid-state salvation on solubility and dissolution rate. In: Brittain HG, ed. Polymorphism in pharmaceutical solids. New York: Marcel Dekker, 279–330.
   Google Scholar
• Yu L, Stephenson GA, Mitchell CA, Bunnell CA, Snorek SV, Bowyer JJ, et al. (2000). Thermochemistry and conformational polymorphism of a hexamorphic crystal system. J Am Chem Soc, 122:585–591.
   Web of Science ®Google Scholar
• Sun C, Grant DJ. (2001). Influence of crystal structure on the tableting properties of sulfamerazine polymorphs. Pharm Res, 18:274–280.
   PubMed Web of Science ®Google Scholar
• Sun C, Grant DJ. (2004). Improved tableting properties of p-hydroxybenzoic acid by water of crystallization: a molecular insight. Pharm Res, 21:382–386.
   PubMed Web of Science ®Google Scholar
• Chen X, Morris KR, Griesser UJ, Byrn SR, Stowell JG. (2002). Reactivity differences of indomethacin solid forms with ammonia gas. J Am Chem Soc, 124:15012–15019.
   PubMed Web of Science ®Google Scholar
• Bernstein J. (2002). Polymorphism in molecular crystals. Oxford, UK: Oxford University Press, 297–307.
   Google Scholar
• Berge SM, Bighley LD, Monkhouse DC. (1977). Pharmaceutical salts. J Pharm Sci, 66:1–19.
   PubMed Web of Science ®Google Scholar
• Gould PL. (1986). Salt selection for basic drugs. Int J Pharm, 33:201–217.
   Web of Science ®Google Scholar
• Stahl PH, Wermuth CG, eds. (2002). Handbook of pharmaceutical salts, properties, selection and use. Weinheim: IUPAC, Wiley-VCH.
   Google Scholar
• Lennernäs H, Abrahamsson B. (2005). The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J Pharm Pharmacol, 57:273–285.
   PubMed Web of Science ®Google Scholar
• Gupta E, Barends DM, Yamashita E, Lentz KA, Harmsze AM, Shah VP et al. (2006). Review of global regulations concerning biowaivers for immediate release solid oral dosage forms. Eur J Pharm Sci, 29:315–324.
   PubMed Web of Science ®Google Scholar
• Kortejärvi H, Urtti A, Yliperttula M. (2007). Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates. Eur J Pharm Sci, 30:155–166.
   PubMed Web of Science ®Google Scholar